| REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19 DM Weinreich, S Sivapalasingam, T Norton, S Ali, H Gao, R Bhore, ... New England Journal of Medicine 384 (3), 238-251, 2021 | 1769 | 2021 |
| Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction AH Gershlick, A Stephens-Lloyd, S Hughes, KR Abrams, SE Stevens, ... New England journal of medicine 353 (26), 2758-2768, 2005 | 748 | 2005 |
| REGEN-COV antibody combination and outcomes in outpatients with Covid-19 DM Weinreich, S Sivapalasingam, T Norton, S Ali, H Gao, R Bhore, J Xiao, ... New England Journal of Medicine 385 (23), e81, 2021 | 625 | 2021 |
| Subcutaneous REGEN-COV antibody combination to prevent Covid-19 MP O’Brien, E Forleo-Neto, BJ Musser, F Isa, KC Chan, N Sarkar, KJ Bar, ... New England Journal of Medicine 385 (13), 1184-1195, 2021 | 467 | 2021 |
| Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial EL Simpson, AS Paller, EC Siegfried, M Boguniewicz, L Sher, ... JAMA dermatology 156 (1), 44-56, 2020 | 430 | 2020 |
| Conjunctivitis in dupilumab clinical trials B Akinlade, E Guttman‐Yassky, M de Bruin‐Weller, EL Simpson, ... British Journal of Dermatology 181 (3), 459-473, 2019 | 388 | 2019 |
| Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo … AS Paller, EC Siegfried, D Thaçi, A Wollenberg, MJ Cork, PD Arkwright, ... Journal of the American Academy of Dermatology 83 (5), 1282-1293, 2020 | 323 | 2020 |
| Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study M Deleuran, D Thaçi, LA Beck, M de Bruin-Weller, A Blauvelt, S Forman, ... Journal of the American Academy of Dermatology 82 (2), 377-388, 2020 | 229 | 2020 |
| Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial M Worm, EL Simpson, D Thaçi, R Bissonnette, JP Lacour, S Beissert, ... JAMA dermatology 156 (2), 131-143, 2020 | 158 | 2020 |
| Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis: results from a phase IIa open‐label trial and subsequent phase III open‐label extension MJ Cork, D Thaçi, LF Eichenfield, PD Arkwright, T Hultsch, JD Davis, ... British Journal of Dermatology 182 (1), 85-96, 2020 | 142 | 2020 |
| Effect of subcutaneous casirivimab and imdevimab antibody combination vs placebo on development of symptomatic COVID-19 in early asymptomatic SARS-CoV-2 infection: a randomized … MP O’Brien, E Forleo-Neto, N Sarkar, F Isa, P Hou, KC Chan, BJ Musser, ... Jama 327 (5), 432-441, 2022 | 105 | 2022 |
| In vivo–in vitro correlation (IVIVC) modeling incorporating a convolution step T O'hara, S Hayes, J Davis, J Devane, T Smart, A Dunne Journal of pharmacokinetics and pharmacodynamics 28, 277-298, 2001 | 81 | 2001 |
| Trial investigators. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19 DM Weinreich, S Sivapalasingam, T Norton, S Ali, H Gao, R Bhore, ... N Engl J Med 384 (3), 238-251, 2021 | 80 | 2021 |
| Grapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations M Gertz, JD Davis, A Harrison, JB Houston, A Galetin Current drug metabolism 9 (8), 785-795, 2008 | 78 | 2008 |
| A phase 2, open‐label study of single‐dose dupilumab in children aged 6 months to< 6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy AS Paller, EC Siegfried, EL Simpson, MJ Cork, B Lockshin, MP Kosloski, ... Journal of the European Academy of Dermatology and Venereology 35 (2), 464-475, 2021 | 76 | 2021 |
| Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development J Wang, S Iyer, PJ Fielder, JD Davis, R Deng Biopharmaceutics & drug disposition 37 (2), 51-65, 2016 | 71 | 2016 |
| Pre-clinical pharmacokinetics of UK-453,061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and use of in silico physiologically based … G Allan, J Davis, M Dickins, I Gardner, T Jenkins, H Jones, R Webster, ... Xenobiotica 38 (6), 620-640, 2008 | 68 | 2008 |
| Exploratory population PK analysis of dupilumab, a fully human monoclonal antibody against IL‐4Rα, in atopic dermatitis patients and normal volunteers P Kovalenko, AT DiCioccio, JD Davis, M Li, M Ardeleanu, NMH Graham, ... CPT: Pharmacometrics & Systems Pharmacology 5 (11), 617-624, 2016 | 60 | 2016 |
| Simultaneous assay of fluoroquinolones and theophylline in plasma by high-performance liquid chromatography JD Davis, L Aarons, JB Houston Journal of Chromatography B: Biomedical Sciences and Applications 621 (1 …, 1993 | 56 | 1993 |
| REGEN-COV antibody cocktail clinical outcomes study in Covid-19 outpatients DM Weinreich, S Sivapalasingam, T Norton, S Ali, H Gao, R Bhore, J Xiao, ... MedRxiv, 2021.05. 19.21257469, 2021 | 55 | 2021 |
Eric SimpsonFrances J. Storrs Medical Dermatology Professor, Dermatology, OHSU在 ohsu.edu 的电子邮件经过验证
